Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

JPMorgan keeps a Neutral rating on Genmab (GMAB) with a DKK 1,700 price target after the company announced that Johnson & Johnson (JNJ) has ...

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of ...

Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.

The Jalapeño Popper Grilled Cheese is available for just $10.99 CAD (or $9.49 USD) at participating Chopped Leaf locations ...

Quvia, the AI-powered QoE platform formerly known as Neuron, today announced Q, a suite of embedded AI tools designed to maximize productivity and efficiency for connectivity, digital operations, and ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to ...